Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03054519 · ClinicalTrials.gov registry record · Phase 3
Improve PAD PERformance With METformin
A Phase 3 study of Peripheral Artery Disease, sponsored by Northwestern University.
- Active
- Registry status
- Phase 3
- Development phase
- 203
- Enrollment target
- 5
- Study locations
NCT03054519 is a Phase 3 study of Peripheral Artery Disease that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 203 participants, above the 123-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (65% higher). The trial reports 5 study locations across 3 states.
The verdict
NCT03054519, a Phase 3 study of Peripheral Artery Disease, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 203 participants
- Enrollment target
- 5
- Study locations
Study Summary
The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
Study Locations (5)
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
Louisiana
- Tulane University - New Orleans
- Ochsner Medical Center - New Orleans
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2017-05-23 |
| Est. Completion | 2025-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03054519
The ClinicalTrials.gov registry entry for NCT03054519 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 123-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (65% higher). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03054519 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Louisiana, Florida.
Frequently Asked Questions
What is clinical trial NCT03054519 about?
NCT03054519 is a clinical study titled "Improve PAD PERformance With METformin". The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease compared to placebo.
What is the current status of trial NCT03054519?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 203 participants. The study started on 2017-05-23. Estimated completion is 2025-11.
What conditions does trial NCT03054519 study?
This clinical trial studies the following conditions: Peripheral Artery Disease.
What interventions are being tested in trial NCT03054519?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG).
Who is sponsoring clinical trial NCT03054519?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03054519 being conducted?
This trial has 5 study locations across Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
The COCOA-PAD II Trial
RECRUITING · Phase 3
-
Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
RECRUITING · Phase 3
-
Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure
COMPLETED · Phase 3
-
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
COMPLETED · Phase 3
-
Response to Exercise and Nitric Oxide in PAD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.